Your session is about to expire
← Back to Search
Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Study Summary
This trial will test a new way to treat AML and MDS using stem cells from a donor followed by targeted therapy.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 51 Patients • NCT03727750Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a blood disorder called secondary MDS.Your kidneys, liver, heart, and lungs are working well enough to participate in the study.You were diagnosed with MDS and have 5% or less myeloblasts in your bone marrow.You have acute myeloid leukemia (AML) and are in your first complete remission (CR) with a family or unrelated donor match, or are in your second CR or CR with incomplete platelet recovery (CRP).Your AML diagnosis must show that at least 10% of your cancer cells have a protein called CD33.
- Group 1: Gemtuzumab Ozogamicin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many volunteers are involved in this research initiative?
"Unfortunately, this medical trial is not presently recruiting for participants. Initially published on November 1st 2011 and last updated September 26th 2022, it has since become inactive. Those searching for clinical trials related to preleukemia can find 1651 active studies while those looking into Gemtuzumab Ozogamicin have 26 alternatives available."
Has Gemtuzumab Ozogamicin received regulatory approval from the US Food and Drug Administration?
"After careful consideration, we evaluated Gemtuzumab Ozogamicin's safety to be a 2. Phase 2 trials have supplied evidence of the drug's security but there is yet no proof that it has effective therapeutic properties."
Is recruitment still underway for this clinical experiment?
"At this moment, no patients are being recruited for the trial posted on November 1st 2011. However, if you seek out alternative studies 1651 trials recruiting participants with preleukemia and 26 examinations employing Gemtuzumab Ozogamicin have opened their doors to volunteers."
Have there been any previous experiments conducted with Gemtuzumab Ozogamicin?
"As of now, there are 26 trials researching Gemtuzumab Ozogamicin with 3 in their concluding phase. Of these 26 studies, the majority are located around Baltimore, Maryland; however, patients can find centres conducting clinical research on this drug at 582 different locations worldwide."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger